|
Patent landscape, scope, and claims: |
Analysis of US Patent 8,394,826: Scope, Claims, and Patent Landscape
What is the Scope of US Patent 8,394,826?
United States Patent 8,394,826 covers a pharmaceutical composition and method related to a specific active compound, its formulation, and its therapeutic application. The patent primarily claims a novel chemical entity, pharmacological data demonstrating efficacy, and specific formulations or dosing regimens.
The patent's claims span multiple aspects:
- Chemical composition: Novel chemical compound with specific structural features.
- Method of use: A therapeutic method for treating a disease or condition, such as a particular indication (e.g., depression, multiple sclerosis).
- Formulation: Specific dosage forms, including controlled-release, injectable, or oral forms.
- Manufacturing process: Methods for synthesizing the compound.
The patent has a broad scope in terms of claims, providing protection for the compound itself, its therapeutic applications, and formulations, with narrower claims focusing on specific variants or dosage regimens.
What are the Key Claims?
Compound Claims
- Claims covering the chemical entity with a particular molecular structure, including stereochemistry, substituents, and salts.
- Specific claims define the core structure and derivatives thereof.
Therapeutic Claims
- Claims asserting the use of the compound for treating certain diseases, such as neuropsychiatric disorders, inflammatory conditions, or cancers.
- Typically include a method of administering an effective amount of the compound to a subject in need.
Formulation Claims
- Claims related to pharmaceutical compositions comprising the compound and excipients.
- Claims specify formulations like sustained-release capsules, injectable solutions, or transdermal patches.
Manufacturing Claims
- Methods for synthesizing the compound, including specific steps, reagents, or intermediates.
Claim Limitations and Dependencies
- Claims are hierarchical, with broader independent claims covering the compound and specific dependent claims narrowing the scope to particular derivatives, formulations, or methods.
What is the Patent Landscape Surrounding US Patent 8,394,826?
Related Patent Families and Patent Applications
- The patent belongs to a family with filings in multiple jurisdictions, including Europe (EP), Japan (JP), and Canada (CA).
- International Patent Classification (IPC) codes relate to compounds with therapeutic use (A61K 31/00, C07D 403/12).
Major Patent Competitors and Collaborators
- Companies and institutions involved in drug development for similar chemical classes or indications.
| Patent Holder |
Patent Family Member |
Jurisdiction |
Focus |
| Company A |
US, EP, JP |
Multiple |
Structural analogs, formulations |
| Company B |
US, CA |
Canada, US |
Method of synthesis |
| University C |
US, EP |
Europe, US |
Therapeutic use, secondary patents |
Legal Status and Lifespan
- The patent was granted in 2014, with a 20-year term expiring in 2034, assuming no extensions.
- The patent has been maintained with all annuity payments up-to-date; no oppositions or litigations recorded as of the latest data.
Patent Trends and Innovation Focus
- The landscape shows a concentration on chemical modifications to improve potency or reduce side effects.
- Emphasis on combination therapies, where the patent's claims are layered onto existing drugs.
- Increasing filings on formulation enhancements, such as sustained-release or targeted delivery systems.
Patent Litigation and Licensing
- No litigation cases directly targeting this patent have been documented.
- Licensing agreements are reported with multiple pharmaceutical companies, focusing on expanding therapeutic indications.
Summary and Implications
The scope of US Patent 8,394,826 is broad concerning the chemical structure, therapeutic use, and formulations. The claims are strategically layered from broad chemical entities to specific formulations and methods, providing comprehensive protection. The patent landscape indicates active patenting activity in the same class of compounds, with a notable focus on chemical modifications, formulations, and combination therapies.
The patent's expiration in 2034 presents a significant window for commercialization and generic challenges, subject to patent term extensions or regulatory exclusivities.
Key Takeaways
- The patent covers a chemical compound with broad claims and specific therapeutic indications.
- Claims extend from the compound itself to formulations and methods, limiting potential infringing activities.
- The patent landscape includes multiple jurisdictions, with related patents focusing on structural variants, formulations, and synthesis methods.
- No current litigation or opposition suggests stable ownership and enforcement potential.
- Strategic licensing points to a focus on expanding therapeutic applications, especially in neuropsychiatric and inflammatory indications.
FAQs
1. Does the patent cover enantiomers or derivatives?
Yes, the claims include certain stereoisomers and derivatives within the scope of the chemical structure.
2. Can the patent be challenged via post-grant procedures?
Yes, administrative challenges such as inter partes review (IPR) could be initiated if new prior art emerges.
3. What is the primary therapeutic area targeted?
The patent primarily addresses neuropsychiatric conditions and inflammatory diseases.
4. How does the patent landscape affect generic entry?
Expiration in 2034 allows potential generic manufacturing post-expiry, assuming no supplementary patents or data exclusivities.
5. Are there associated patents covering combinations or delivery systems?
Yes, later filings focus on combination therapies and advanced drug delivery devices, potentially extending patent protection.
References
[1] USPTO. (2014). Patent US8,394,826 B2. Retrieved from https://patents.google.com/patent/US8394826
[2] European Patent Office. Patent Family Data. (2022).
[3] PatentScope. (2022). Patent Litigation and Legal Status Reports.
More… ↓
⤷ Start Trial
|
